Logo

DiagnoCure, Lab21 Ink UK Sales Pact

Oct 05, 2009

NEW YORK (GenomeWeb News) - DiagnoCure said today that Lab21 will sell its colorectal cancer staging test in the UK and Ireland.

Under the exclusive agreement, Lab21 will promote and sell the Previstage GCC Colorectal Cancer Staging Test in the two countries as part of its oncology testing services. DiagnoCure said that it will process the patient samples in its clinical lab in the US.

The company said that around 9,600 people in the UK could benefit from using the test for planning treatment staging each year.

Filed under

Diagnostics
Lab21
DiagnoCure
Breaking News
The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.